Open Access<p>In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin</p>
Author(s) -
Charlaine A. Aventurado,
Junie B. Billones,
Ross D. Vasquez,
Agnes L. Castillo
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s271952
Subject(s) - angiogenesis , in ovo , pharmacology , chorioallantoic membrane , cancer research , neovascularization , biology , vascular endothelial growth factor , in silico , chemistry , biochemistry , microbiology and biotechnology , vegf receptors , embryo , gene
Cancer is considered as one of the deadliest human diseases today. Angiogenesis, the propagation of new blood vessels from pre-existing vasculature, is a critical step in the progression of cancer as it is essential in the growth and metastasis of tumors. Hence, suppression of angiogenesis is a promising approach in cancer therapy. Syringin, a phenylpropanoid glycoside with a molecular formula of C 17 H 24 O 9 , has been found to exhibit chemopreventive effects. However, its anti-angiogenic activity and the underlying mechanism of action are still unknown.